Point72 Asset Management Reports 2.0% Stake in Damora Therapeutics (GLTO) via Schedule 13G/A

On May 15, 2026, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen filed a Schedule 13G/A reporting a new beneficial ownership position in Damora Therapeutics, Inc. (formerly known as Galecto, Inc., ticker: GLTO). As of the event date on March 31, 2026, the reporting persons collectively held 1,193,708 shares of common stock, representing a 2.0% ownership stake in the company. The filing indicates an increase from a previous 0.0% position, with the shares valued at approximately $34.25 million. Point72 Asset Management serves as the investment manager for the fund holding the shares, while Point72 Capital Advisors Inc. acts as its general partner. Steven A. Cohen controls both entities. The reporting persons indicated that the shares were acquired for investment purposes and not with the intent to influence or change the control of the issuer. This amendment updates the previous filing status to reflect the current holdings as of the end of the first quarter of 2026.